Antibacterial Agents TRIZ Cases

RT-PCR measurement of circulating Alu RNA ratios helps predict infection severity and guides MIR-498 or Alu RNA immune enhancement.

A multi-compound composition disrupts cellular lipid rafts to block enveloped virus entry while reducing inflammation and limiting cytotoxicity.

Selective N-tetrazolyl aryl urea derivatives target the bradykinin B1 receptor to curb inflammation and pain while limiting B2-related side effects.

Using hemangioblasts as an intermediate yields large numbers of youthful MSCs with lower senescence, better dispersibility, and retained therapeutic potency.

Modified amino lipids in composite nanoparticles improve mRNA encapsulation and cell uptake while lowering immunogenicity in mammalian delivery.

mRNA-encoded transposase with minicircle DNA enables stable lymphocyte gene integration with higher transfer rates and lower toxicity.

Crystalline oral beta-lactamase inhibitor forms protect beta-lactam antibiotics from enzyme deactivation and improve treatment of resistant bacteria.

Boron-containing inhibitors target serine and metallo-beta-lactamases while improving oral bioavailability and reducing dosage burden.

Novel FabI inhibitor compounds improve membrane penetration and avoid cross-resistance in resistant Gram-negative and Gram-positive bacteria.

Controlled phenol treatment doubles CS6 surface presentation while inactivating E. coli, enabling lower-load oral vaccines with fewer adverse effects.

Thiol-reactive linker chemistry enables site-specific ADC conjugation with controlled drug ratios, lower off-target toxicity, and more consistent products.

Compounds that block ESX-1 and ESX-5 secretion help suppress drug-resistant mycobacteria despite the cell envelope permeability barrier.

A gut-adapted probiotic strain inhibits Salmonella after infection, easing diarrhea and inflammation without antibiotic-driven flora imbalance.

Small-molecule biphenyl fluorine derivatives block PD-1/PD-L1 binding to restore T cell activation and improve tumor immunoreactivity.

Selected high-titer donor plasma creates immunoglobulin with more consistent respiratory pathogen coverage and longer protection for immunodeficient patients.

Compounds such as NPIMA and BPOET target persister and VBNC bacteria, enabling eradication in infections, biofilms, and on surfaces.

Isolated Dolosigranulum pigrum strains suppress respiratory pathogens while restoring microbiota, offering an antibiotic-sparing option.

Specific L. delbrueckii strains use pyruvate oxidase to generate hydrogen peroxide, suppressing P. gingivalis for preventive periodontal care.

Modified adenoviral fiber proteins bind DSG2 to bypass inaccessible CAR and CD46 receptors, improving epithelial tissue delivery.

Blending black, red, and yellow maca roots helps lower inflammatory cytokines while improving libido and sexual function with fewer side effects.

Novel ring-fused thiazolino 2-pyridones help treat resistant gram-positive infections and can boost vancomycin efficacy.

Engineered synthetic microorganisms replace pathogens after decolonization to stabilize the microbiome, reduce recurrence, and improve safety.

Humanin analogs such as colivelin target endothelial dysfunction in sepsis to reduce organ injury, inflammation, and neutrophil infiltration.

Medium chain fatty acid salts in a hydrophobic oral suspension transiently open GI tight junctions to improve bioavailability without injections.

Modified LNPs with cholesterol substitutes suppress innate immune responses and reduce immune cell toxicity during in vivo mRNA delivery.

Macolacin analogs modify the colistin scaffold to retain antibacterial activity against mcr-1 resistant pathogens and expand antibiotic options.

A polymer-stabilized spray-dried mRNA-LNP powder prevents aggregation and preserves mRNA integrity for storage and inhaled delivery.

Engineered bacteriophages deliver CRISPR-Cas and colicins to kill Escherichia, cut bacterial loads, and mitigate resistance.

Targeted RAR and AHR agonist delivery boosts CD8+ T-cell trafficking to the colon while limiting off-target effects through local nanoparticle action.

A modified TCP-25 polypeptide tackles wound infection and inflammation together, promoting healing while reducing toxicity and scar hyperplasia.

VHH fusions co-neutralize S. aureus alpha- and gamma-hemolysins, blocking toxin damage when antibiotics alone leave virulence active.

Electron-withdrawing substituents and cyclodextrin formulations help albicidin derivatives resist hydrolysis while improving solubility and bioavailability.

Selective IL1RAP-binding antibodies block IL-1 signaling and CAN04 binding to improve cancer targeting and cytotoxic activity.

A SHEN26 solid oral formulation uses excipient combinations to improve dissolution, release rate, stability, and bioavailability for coronavirus treatment.

Segmented Bordetella epitope megapools improve T cell detection precision and help distinguish infection and post-vaccination states.

Engineered stem cells co-expressing TCR and CAR create a sustained T-cell supply for multi-antigen tumor killing with lower cytokine storm risk.

A phenylquinolone scaffold is tuned to overcome bacterial resistance while retaining anticancer activity and low liver-kidney impact.

A five-strain probiotic blend targets flora imbalance, barrier damage, inflammation, and oxidative stress to help prevent treatment-related diarrhea.

S. hominis and S. epidermidis probiotics produce hogocidins in situ to target skin pathogens while preserving natural flora and immune defense.

Low solubility weakens vinegar’s bioactive preservation effects; α-cyclodextrins and spray-drying improve stability.

Antibody variants target polymorphic human SIRP-α and related species while blocking or reducing CD47 binding for immune-response research.

Receptor binding and pore formation let plant-expressed salmocins reduce Salmonella contamination across major pathogenic strains without heat.

Conventional CFS and IBS therapies may have limited efficacy and side effects; GOLDGUT-BB21 supports gut barrier function and inhibits pathogens.

Bacterial products from sea lice microbiota prime fish immunity, induce parasite dysbiosis, and reduce reliance on harmful chemical treatments.

Microbial consortia modify the rumen microbiome to improve feed digestion, milk yield, and desirable milk components without scaling livestock numbers.

This case adds terpenes after cannabinoid extraction to offset processing losses in compositions for male urogenital disorders.

Batch Isoniazid production uses solvent-intensive workup; continuous flow carries isonicotinamide directly into hydrazine reaction without isolation.

Benzamide agents treat resistant bacterial infections, including MRSA and vancomycin-resistant strains, with improved solubility and delivery.

Bacteriophage compositions target resistant NTM bacteria, offering an alternative to conventional antibiotics for difficult infections.

This case addresses limited metabolic stability in CD73 inhibitors through modified compounds that block AMP-to-adenosine conversion.

Triazole-substituted arylamide derivatives constrain P2X3 receptor activity, resolving the trade-off between therapeutic effectiveness and compound complexity.

Astrovirus-derived synthetic peptides bind C1q and MBL to inhibit classical and lectin pathways, reducing tissue damage in autoimmune diseases.

Respirable dry powders deliver therapeutic agents to the respiratory tract using anion exchange reactions and spray drying.

Small molecule compounds block PD-1 and PD-L1 interactions to restore T cell functionality, avoiding monoclonal antibody complexity.

X-shaped nucleic acid compositions hybridize with target molecules to form multifunctional nano-architectures.

Blending oregano oil with polyionic enhancers overcomes limited cellular uptake to boost bacterial-fighting capability in veterinary applications.

Protease-deficient E. coli strains enable periplasmic secretion of diphtheria toxin, preventing proteolytic degradation and improving vaccine yield.

Thiotriazoles react with electrophiles to form thiotetrazole compounds, avoiding hazardous reagents and improving synthesis safety.

Heterobicyclic compounds inhibit Class A, C, and D beta-lactamases via active site binding, countering rising multi-drug resistance rates.

Engineered amino acid motifs allow isoprenoid transferases to attach drugs at defined sites, resolving non-uniformity from random lysine bonding.

Segmenting the synthesis into modular stages resolves the trade-off between backbone modification versatility and manufacturing complexity.

Virus-like particle vaccines with adjuvants resolve the contradiction between antibody production and protective immunity against norovirus.

Specific Lactobacillus strains restore healthy flora and modulate immune response without disrupting natural microbiota.

Combining leucocidin M/F antigen with somatic antigens prevents Staphylococcus aureus mastitis by neutralizing toxins despite isolate variation.

Synthesizes a chlorophenyl oxadiazole amidine compound using carbonyldiimidazole catalysis to demonstrate antimicrobial activity.

Liquid propylene glycol formulation dissolves pimobendan and ACE inhibitors to enhance oral bioavailability.

Crosslinked micelles resist dilution during circulation to enhance drug accumulation in diseased tissues.

A hardenable acrylic composition stabilizes polymer beads in an aqueous dispersion through controlled water content equilibrium.